Barclays Issues Pessimistic Forecast for Agilon Health (NYSE:AGL) Stock Price

Agilon Health (NYSE:AGL) had its price objective lowered by equities researchers at Barclays from $1.50 to $1.00 in a report issued on Thursday,Benzinga reports. The brokerage currently has an “underweight” rating on the stock. Barclays‘s price objective would indicate a potential upside of 51.06% from the company’s previous close.

AGL has been the subject of several other research reports. Weiss Ratings restated a “sell (e+)” rating on shares of Agilon Health in a research report on Wednesday, October 8th. Jefferies Financial Group lowered their price target on shares of Agilon Health from $2.40 to $1.10 and set a “hold” rating on the stock in a report on Friday, August 15th. Wells Fargo & Company reduced their target price on Agilon Health from $1.50 to $1.00 and set an “overweight” rating for the company in a research report on Wednesday. Sanford C. Bernstein reissued a “market perform” rating and issued a $1.40 price target (down previously from $4.00) on shares of Agilon Health in a report on Wednesday, August 20th. Finally, Robert W. Baird decreased their price objective on Agilon Health from $5.00 to $1.00 and set a “neutral” rating on the stock in a report on Thursday, August 14th. Four analysts have rated the stock with a Buy rating, twelve have issued a Hold rating and two have assigned a Sell rating to the company’s stock. According to MarketBeat, Agilon Health has a consensus rating of “Hold” and a consensus price target of $2.73.

Agilon Health Stock Down 5.0%

AGL stock opened at $0.66 on Thursday. The firm has a market capitalization of $274.45 million, a PE ratio of -0.88 and a beta of 0.05. The stock’s 50 day moving average is $1.02 and its 200-day moving average is $1.82. Agilon Health has a twelve month low of $0.64 and a twelve month high of $6.08.

Agilon Health (NYSE:AGL) last posted its earnings results on Tuesday, November 4th. The company reported ($0.27) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.18) by ($0.09). Agilon Health had a negative return on equity of 75.92% and a negative net margin of 5.24%.The firm had revenue of $1.44 billion during the quarter, compared to the consensus estimate of $1.43 billion. Agilon Health has set its FY 2025 guidance at EPS. On average, equities research analysts anticipate that Agilon Health will post -0.59 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Agilon Health

A number of hedge funds and other institutional investors have recently modified their holdings of the company. CenterBook Partners LP raised its stake in Agilon Health by 492.4% in the third quarter. CenterBook Partners LP now owns 11,428,027 shares of the company’s stock valued at $11,771,000 after buying an additional 9,499,012 shares in the last quarter. Nuveen LLC acquired a new position in Agilon Health in the first quarter valued at approximately $17,242,000. Marshall Wace LLP increased its stake in Agilon Health by 3,590.4% in the second quarter. Marshall Wace LLP now owns 1,484,114 shares of the company’s stock valued at $3,413,000 after purchasing an additional 1,443,898 shares during the last quarter. Norges Bank acquired a new stake in Agilon Health during the second quarter worth approximately $3,299,000. Finally, JPMorgan Chase & Co. lifted its position in shares of Agilon Health by 209.5% during the 3rd quarter. JPMorgan Chase & Co. now owns 2,105,297 shares of the company’s stock worth $2,168,000 after buying an additional 1,425,052 shares during the last quarter.

About Agilon Health

agilon health, inc. provides healthcare services for seniors through primary care physicians in the communities of the United States. It offers a platform that manages the total healthcare needs of the patients by subscription-like per-member per-month. The company was formerly known as Agilon Health Topco, Inc and changed its name to agilon health, inc.